gbola amusa md cfa head hc research
sale trade et
viral news genet medicin gensight see posit french auth nh data
highlight week decemb decemb gensight biolog buy share trade week
posit decemb gensight announc first temporari author use atu franc
gene therapi gt lumevoq lhon us news potenti lead indic eu approv
ahead guid file along posit contribut decemb upgrad sight
neutral buy gensight decemb subsequ announc find realiti natur
histori nh studi show nh data contrast ed sharpli bilater visual improv observ
phase revers rescu studi us nh data increas probabl
profound efficaci potenti explained/support recent nhp data suggest therapeut gene transfer
inject eye uninject contralater eye uniqur buy chardan top pick announc updat
data poster phase iib trial gt hemophilia hemb sustain mean factor ix
activ observ patient vs normal year singl iv administr
gc/kg note declin mean activ patient month
month uniqur also report updat phase i/ii data year show
mean annual bleed rate declin replac therapi despit produc mean
activ year versu year balanc view
updat dataset support best-in-class first-in-class ablest-to-manufacture-in-class statu
blockbust potenti among hemb actual predict avx bold mdco
nite uniqur remain top idea genet medicin unrat announc
fda acceler approv antisens oligonucleotid aso vyondi golodirsen treatment duchenn
muscular dystrophi dmd patient amen exon skip vyondi subject confirm clinic
benefit post-market studi data phase essenc trial current enrol along
exondi eteplirsen vyondi compani approv exon-skip therapi dmd
look forward decemb decemb happi holiday
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
gene express new technolog improv deliveri gene edit therapi
effici viral-bas deliveri crispr/ca system vivo therapeut applic limit poor tissue-specif
target ineffici cell entri immun system activ mani case complex manufactur protocol non-
viral deliveri method low immunogen simplifi manufactur promis altern current
predominantli aav-bas deliveri decemb issu scienc advanc jordan green john hopkin
publish synthesi new class hyperbranch cation poli -amino ester pbae abl form
nanoparticl capabl function deliveri kda protein notabl polym termin ligand
moder hydrophob demonstr superior intern endosom escap thu underscor necess
optim particl composit function outcom polym abl deliv function
rnp vitro crispr edit effici report cell respect
robust vivo test deliveri system perform mous model brain cancer show evid gene
edit day intracrani infus key take-away studi us self-assembl
nanoparticl could deliv relev protein cargo cytosol target cell
pleas refer import disclosur inform regul analyst certif found page report
commonli use non-vir deliveri method molecular biolog mixtur nucleic acid cation lipid
rnai-bas therapeut onpattro buy exampl formul inject lipid
complex intellia buy deliv compon lipid nanoparticl posit charg
lipoplex interact well glycoprotein cell surfac facilit cellular uptak though note advanc develop
altern deliveri approach simpler manufactur improv specif safeti buy
genedit privat announc partnership decemb develop non-vir non-lipid deliveri nucleic
acid protein-nucl acid complex specif tissu genedit report preclin proof concept gene
edit follow deliveri ribonucleoprotein tissu relev duchenn muscular dystrophi fragil
syndrom potenti deliv enzym cell rather mrna encod enzym allow potenti
reduc off-target edit effect lower immunogen
qure buy activ bleeds/prophi decemb amusa
uniqur announc updat data poster on-going phase iib trial gene therapi gt
hemophilia hemb show mean activ normal week
compar activ report month uniqur also report updat phase i/ii data
show year mean annual bleed rate declin
replac therapi despit associ mean activ
updat dataset us continu support blockbust potenti
best-in class first-in-class ablest-to-manufacture-in-class profil among hemb though declin
activ month month trend worth monitor level well
level need breakthrough result level seen produc good outcom
uniqur remain top idea genet medicin potenti allow hemophilia
patient live phenotyp normal life potenti huntington diseas proof-of-concept dataset
expect transform uniqur toward valuat consist unrat
buy pt process data fa surpris lad-i decemb livshit
present preliminari data ex vivo lentivir gene therapi fanconi anemia
fa manufactur commercial-grad process data demonstr higher product vector copi
number vcn vs process product signal engraft patient month broadli fact
made commercial-grad vector process align data prior patient achiev
phenotyp correct us posit signal feasibl commerci
rocket addit present data patient treat leukocyt adhes defici
patient reach transgen express month post treatment exceed target threshold
consider margin lad-i patient result extend addit patient see consider posit
read-across rocket remain ex vivo pipelin
given increas visibl process read-across rocket ex vivo program updat data
support efficaci increas probabl success fa leukocyt adhes deficiency-
pyruv kinas defici drive pt
sight upgrad buy eu opportun french auth arriv decemb amusa
upgrad gensight biolog buy appar eu de-risk gensight phase asset
gt lumevoq leber hereditari optic neuropathi follow announc first
temporari author use atu franc ahead submiss
recal prior caution sight phase revers rescu trial fail meet primari endpoint
show lack statist differ sham-treat eye concern lack nh
data support notion visual improv sham treat eye due treatment
 gensight announc attain atu franc lead signal ema approv
provid factor contribut upgrad neutral buy mm eu sale
 new nhp data may support potenti contralater effect reverse/rescu
 realiti natur histori nh studi soon report result interim data final data thu
provid potenti regulatori support bilater effect improv nh
 santhera pharmaceut unrat nh data data provid support regul
 faster path market like exist europ note raxon approv contrast us
 phase reflect data due potenti address open regulatori issu
page
 sight share declin valu big biopharma re-pric valu aav-bas gt asset platform
 opportun upsid sight us outweigh risk dilut
edita medicin present updat preclin data ex vivo gene editing-bas asset scd show
clean off-target edit profil robust fetal hemoglobin hbf induct upon engraft mice
leverag nucleas technolog coupl guid rna modif yield
edit effici healthi donor hematopoiet stem cell addit hbf induct level
vivo mous data show red blood cell rbc posit hbf see encourag
discuss novemb research edita asset come behind lentivir gene therapi gt gene
edit ge approach along recently-approv non-genet medicin asset anticip edita would need
show best-in-class profil gain eventu market share us data suggest definit still
game provid anim data translat clinic
gensight biolog announc interim find patient enrol realiti natur histori nh studi
support efficaci gt lumevoq phase revers rescu studi analysi
show nh result contrast sharpli bilater visual improv observ phase studi
earli result us increas probabl efficaci efficaci profound
consist nhp data may contralater effect untreat eye due
therapeut gene transfer inject eye uninject contralater eye primat
xcur encourag initi data decemb naka
exicur announc preliminari find compani phase ib/ii clinic trial evalu
spheric nucleic acid combin pembrolizumab patient advanc solid tumor
date patient enrol dose treatment-rel seriou advers event
dose-limit toxic report final dose escal cohort open enrol
term activ drug shown produc cytokin chemokin express immun cell
activ blood treat patient indic desir immun activ occur dose
advanc phase ii trial combin pembro expans cohort merkel cell carcinoma
cutan squamou cell carcinoma patient respond therapi
genet medicin news decemb decemb
unrat announc data rapid person manufactur recombin t-cell decemb
unrat announc unrat data pi trial t-cell r/r mm decemb
unrat announc result trial car-t tx r/r mcl decemb
ucsf publish method increas genom edit effici decemb
unrat announc data pi/ii studi ex vivo gene edit cell tx tdt decemb
sangamo report data partner sanofi unrat patient phase i/ii thale
studi transfusion-depend beta thalassemia tdt report advers event consist
known issu associ apheresi mobil busulfan condit
patient on-target edit effici therapeut product respect
patient show respect hbf level g/dl patient sinc resum receiv pack
red blood cell transfus notabl lack concord edit effici hbf level
time data cutoff patient dose compani plan enrol final patient
report addit data note engraft and/or hbf level may increas time current
dataset show lower hbf induct compar report crispr buy asset
bluebird bio unrat ex vivo lentivir gt program see
unrat announc data real-world use car-t therapi yescarta r/r dlbcl decemb
unrat announc lift clinic hold relat piii trial gt rdeb decemb
unrat appoint eli wallac cso resid oncolog program decemb
buy announc appoint jean franchi cfo decemb
page
unrat announc updat data ex vivo lv-base gt lentiglobin tdt decemb
bluebird bio announc updat data sever on-going trial lentiglobin tdt data year
follow-up phase i/ii northstar trial present show patient
genotyp free red blood cell transfus month transfus volum reduc
patient achiev transfus independ patient genotyp
transfus independ ti durat month data cutoff
result phase trial show evalu patient achiev ti
patient least month follow-up free transfus least month level lentiglobin
transgen stabl month g/dl g/dl g/dl total hemoglobin level
patient median g/dl g/dl g/dl
patient enrol phase treat least month
follow-up achiev maintain transfus independ least month follow-up
receiv transfus month last follow-up
buy announc unrat patent gener induc pluripot stem cell decemb
cyad unrat announc updat autolog car-t program decemb
buy announc appoint dr franoi nader board director decemb
unrat announc interim data pi/iia trial car-t tx r/r nhl decemb
precis bioscienc announc updat interim data phase trial off-the-shelf allogen car-
patient relapsed/refractori non-hodgkin lymphoma nhl cell acut lymphocyt leukemia
receiv either cells/kg cells/kg singl infus follow day lymphodeplet
evid graft-versus-host diseas sae report though patient develop grade cytokin
releas syndrom patient experienc grade neurotox resolv
efficaci patient show evid tumor shrinkag timepoint among nhl patient patient
achiev object respons partial respons complet respons high dose level remain
patient achiev respons day show diseas progress day patient
cohort achiev complet respons show respons day
note precis report dose-depend increas car-t expans persist suggest higher
dose level could boost durat respons dose cohort cells/kg data anticip
inscripta privat announc mm seri autom genom scale engin decemb
unrat present preclin data off-the-shelf ipsc-deriv car-t therapi decemb
unrat announc updat clinic data ex vivo lv-base gt x-scid decemb
buy announc price public offer common stock decemb
freelin privat announc appoint julia gregori board director decemb
locana privat announc appoint dr jame burn ceo decemb
buy announc ind file pi studi rnai-bas tx clear cell rcc decemb
unrat announc privat placement mm convert note decemb
unrat announc pi data neoantigen-bas tx slate granit solid tumor decemb
prqr buy announc patient dose pi/ii trial rna oligonucleotid adrp decemb
cyad unrat announc updat autolog car-t program r/r aml decemb
celyad provid updat progress test phase think deplethink trial
patient enrol think trial biweekli dose without condit report grade
treatment-rel advers event patient experienc cytokin releas syndrom grade grade
dose limit toxic report high dose billion cell efficaci anti-leukem activ
short durat primarili patient non-advers aml non-veri high md risk categori compani
plan enrol patient expans cohort test produc optimab process optim
enrich t-cell memori phenotyp
patient enrol deplethink trial precondit patient experienc grade
grade car-t encephalopathi anoth experienc grade precondit associ
page
improv dose-depend engraft object respons report date compani plan
dose-escal billion cell per infus
compani novemb initi phase trial autolog car-t
incorpor shrna technolog design target ligand mica micb improv engraft
persist enrol expect begin
genedit privat announc licens agreement collab edita buy gt deliveri decemb
blcm unrat announc licens agreement md anderson caspacid tech decemb
unrat announc bla file car-t cell therapi r/r mcl decemb
vyriad privat announc edwin kania nathan staci join board director decemb
unrat collabor unrat trial yescarta r/r dlbcl decemb
stanford publish gene edit andautolog airway stem cell transplant decemb
tng fp unrat announc binv se unrat preclin data ov decemb
unrat announc updat busi oper decemb
miragen therapeut announc phase ii solar trial microrna-bas therapeut cobomarsen cutan
t-cell lymphoma stop enrol patient trial design enrol patient instead enrol around
compani believ data smaller set patient provid safeti efficaci data shorter period
time requir fewer resourc top-line data expect
compani also report pipelin develop primarili focus develop preclin
microrna mimic idiopath pulmonari fibrosi
miragen also execut plan reduc cost streamlin oper includ reduct employe count
tng fp unrat announc trial ov opdivo miss primari endpoint decemb
unrat announc fda approv aso-bas therapeut vyondi dmd decemb
sarepta announc fda grant acceler approv antisens oligonucleotid vyondi
duchenn muscular dystrophi part acceler approv process sarepta must submit post-market data
phase essenc trial confirm clinic benefit
recal august compani announc receiv complet respons letter respons
nda seek acceler approv golodirsen dmd letter cite concern name risk infect
relat iv administr renal toxic associ aso follow formal disput sarepta offic
new drug ond grant compani appeal re-submit nda review approv
unrat announc mm non-dilut senior secur loan financ decemb
unrat win unrat mm yescarta-rel lawsuit decemb
compani mention report
page
page
select catalyst genet medicin coverag
figur regenxbio rocket solid uniqur expect import data read-out
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
dcr-hbv anticip first interim data clinic trial hbv
submit ind methylmalon acidemia mma
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
initi dose phase trial hemophilia
report biomark data phase i/ii ignit dmd trial
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
present preclin data new gt program fabri pomp defici
file ind cta pomp diseas
provid updat phase i/ii studi hemophilia
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
page
select catalyst outsid genet medicin coverag
suvodirsen interim data open-label extens studi dmd
initi phase ib trial beta-thalassemia
initi clinic trial charcot-marie-tooth type
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind inherit amyotroph later sclerosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
file ind gangliosidosi
dose patient optim lenti vector trial fabri diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end dec vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm gensight genet therapytickerratingccm ptupsideclosechang changemc mm gene editingtickerratingccm ptupsideclosechang changemc mm homolog pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
